See more : Quest Diagnostics Incorporated (0KSX.L) Income Statement Analysis – Financial Results
Complete financial analysis of electroCore, Inc. (ECOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of electroCore, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- RELX PLC (REL.L) Income Statement Analysis – Financial Results
- Parkway Acquisition Corp. (PKKW) Income Statement Analysis – Financial Results
- Kiora Pharmaceuticals, Inc. (KPRX) Income Statement Analysis – Financial Results
- VetaNova, Inc. (VTNA) Income Statement Analysis – Financial Results
- Bajaj Finserv Ltd. (BAJAJFINSV.NS) Income Statement Analysis – Financial Results
electroCore, Inc. (ECOR)
About electroCore, Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.03M | 8.59M | 5.45M | 3.50M | 2.39M | 992.95K | 811.46K | 254.14K |
| Cost of Revenue | 2.80M | 1.62M | 1.39M | 1.74M | 1.16M | 578.74K | 518.53K | 123.73K |
| Gross Profit | 13.23M | 6.98M | 4.07M | 1.76M | 1.23M | 414.21K | 292.93K | 130.41K |
| Gross Profit Ratio | 82.51% | 81.19% | 74.59% | 50.30% | 51.59% | 41.71% | 36.10% | 51.31% |
| Research & Development | 5.32M | 5.52M | 2.54M | 4.20M | 9.90M | 12.47M | 7.83M | 7.97M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.50M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.71M | 24.33M | 21.57M | 21.84M | 35.42M | 42.50M | 18.11M | 7.17M |
| Other Expenses | 0.00 | -6.00K | -8.30K | -17.80K | -12.00K | -344.91K | -4.89K | 7.17M |
| Operating Expenses | 32.03M | 29.85M | 24.11M | 26.04M | 45.32M | 54.97M | 25.94M | 15.14M |
| Cost & Expenses | 34.84M | 31.47M | 25.49M | 27.78M | 46.48M | 55.55M | 26.46M | 15.26M |
| Interest Income | 433.00K | 287.00K | 10.70K | 84.30K | 970.59K | 1.01M | 99.03K | 0.00 |
| Interest Expense | 0.00 | 287.00K | 0.00 | 8.34K | 0.00 | 0.00 | 7.12M | 771.25K |
| Depreciation & Amortization | 1.03M | 596.00K | 436.62K | 489.47K | 307.36K | 66.66K | 32.31K | 53.43K |
| EBITDA | -17.76M | -22.33M | -19.66M | -24.18M | -43.98M | -54.49M | -28.87M | -14.96M |
| EBITDA Ratio | -110.79% | -266.22% | -403.85% | -681.37% | -1,761.26% | -5,420.74% | -3,144.73% | -5,885.31% |
| Operating Income | -18.81M | -22.87M | -20.04M | -24.28M | -44.09M | -54.55M | -25.64M | -15.01M |
| Operating Income Ratio | -117.31% | -266.22% | -367.68% | -694.66% | -1,844.81% | -5,494.07% | -3,160.31% | -5,906.33% |
| Total Other Income/Expenses | -215.00K | 281.00K | 1.97M | -398.04K | -1.04M | -1.21M | -10.38M | -771.25K |
| Income Before Tax | -19.02M | -22.59M | -18.07M | -24.68M | -45.13M | -55.76M | -36.03M | -15.78M |
| Income Before Tax Ratio | -118.65% | -262.95% | -331.47% | -706.05% | -1,888.24% | -5,615.88% | -4,440.01% | -6,209.81% |
| Income Tax Expense | -186.00K | -431.00K | -851.20K | -1.17M | 18.00K | 2.43K | 6.88M | -44.15K |
| Net Income | -18.83M | -22.16M | -17.22M | -23.51M | -45.15M | -55.82M | -35.79M | -15.74M |
| Net Income Ratio | -117.49% | -257.94% | -315.86% | -672.55% | -1,889.00% | -5,621.66% | -4,410.88% | -6,192.44% |
| EPS | -3.42 | -4.69 | -4.36 | -9.04 | -23.05 | -28.61 | -1.36 | -1.57 |
| EPS Diluted | -3.42 | -4.69 | -4.36 | -9.04 | -23.05 | -28.61 | -1.36 | -1.57 |
| Weighted Avg Shares Out | 5.52M | 4.73M | 3.95M | 2.60M | 1.96M | 1.95M | 26.34M | 10.04M |
| Weighted Avg Shares Out (Dil) | 5.52M | 4.73M | 3.95M | 2.60M | 1.96M | 1.95M | 26.34M | 10.04M |
Ecora Resources to get cobalt royalty boost from Voisey's Bay expansion
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) has noted yesterday's confirmation from operator Vale that it had completed the Voisey's Bay Mine Expansion Project. Royalty specialist Ecora has a stream agreement which entitles it to 22.82% of all cobalt production from the Voisey's...
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21
ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place in...
electroCore, Inc. (ECOR) Q3 2024 Earnings Call Transcript
electroCore, Inc. (NASDAQ:ECOR ) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Swayampakula Ramakanth -...
ElectroCore, Inc. (ECOR) Reports Q3 Loss, Tops Revenue Estimates
ElectroCore, Inc. (ECOR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.68 per share a year ago.
electroCore Announces Third Quarter 2024 Financial Results
Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales
ElectroCore's Truvaga™ Plus Wins Men's Health Magazine Tech Award
ROCKAWAY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness product, Truvaga Plus, has been awarded the prestigious Men's Health Magazine Tech Award...
Strength Seen in electroCore (ECOR): Can Its 6.0% Jump Turn into More Strength?
electroCore (ECOR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freeburg will join electroCore, effective November 11, 2024, as the Company's VP, Corporate Controller. The...
Ecora Resources notes upgrades at Maracás Menchen vanadium project
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) has noted an update to the Life of Mine and Pre-Feasibility Study completed on the Maracás Menchen vanadium-titanium operation in Bahia State, Brazil by owner Largo. The highlights of the LOMP and Pre-Feasibility Study include...
Ecora Resources' comments about Voisey Bay encouraging, broker says
Ecora Resources PLC's (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) comments regarding the Voisey's Bay cobalt operation stream were the most significant component of its third quarter update, according to Peel Hunt. The four deliveries in the quarter matched the total deliveries for all of...
Source: https://incomestatements.info
Category: Stock Reports